Fate Therapeutics Announces September Investor Events

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced its participation in several investor conferences scheduled for September 2020, including the Baird Global Healthcare Conference and the Citi 15th Annual BioPharma Conference. The company, known for its innovative cellular immunotherapies for cancer and immune disorders, is set to present at multiple venues over the course of the month. Interested investors can access live webcasts on the company’s investor relations website, with archived replays available shortly thereafter.

Positive

• Involvement in multiple prestigious investor conferences enhances visibility and investor engagement.
• Fate Therapeutics showcases commitment to advancing its cellular immunotherapy projects.
• Opportunity to attract potential investors and partnerships through conference participation.

Negative

• None.

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:

• Baird Global Healthcare Conference on Wednesday, September 9, 2020.
• Citi 15^th Annual BioPharma Conference on Wednesday, September 9, 2020.
• Wells Fargo Healthcare Conference on Thursday, September 10, 2020.
• Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 15, 2020.
• H.C. Wainwright 22^nd Annual Global Investment Conference on Tuesday, September 15, 2020.
• Oppenheimer 30^th Annual Healthcare Conference on Tuesday, September 29, 2020.

A live webcast, if recorded, of each presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following each live webcast, an archived replay will be available on the Company's website.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

What conferences is Fate Therapeutics participating in September 2020?

Fate Therapeutics is participating in the Baird Global Healthcare Conference, Citi 15th Annual BioPharma Conference, Wells Fargo Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, H.C. Wainwright 22nd Annual Global Investment Conference, and Oppenheimer 30th Annual Healthcare Conference.

What is the focus of Fate Therapeutics?

Fate Therapeutics focuses on developing first-in-class cellular immunotherapies for cancer and immune disorders.

Where can I find live webcasts of Fate Therapeutics presentations?

Live webcasts of Fate Therapeutics presentations can be accessed through the investor relations section of their website.

What product candidates does Fate Therapeutics have?

Fate Therapeutics' immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, while their immuno-regulatory candidates include ProTmune™.